Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence.

Lionakis MS, Lewis RE, May GS, Wiederhold NP, Albert ND, Halder G, Kontoyiannis DP.

J Infect Dis. 2005 Apr 1;191(7):1188-95. Epub 2005 Feb 28.

2.
3.

Fruit flies as a minihost model for studying drug activity and virulence in Aspergillus.

Lionakis MS, Kontoyiannis DP.

Med Mycol. 2005 May;43 Suppl 1:S111-4. Review.

PMID:
16110801
4.

Drosophila melanogaster as a model organism for invasive aspergillosis.

Lionakis MS, Kontoyiannis DP.

Methods Mol Biol. 2012;845:455-68. doi: 10.1007/978-1-61779-539-8_32.

5.

Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis.

Ben-Ami R, Lamaris GA, Lewis RE, Kontoyiannis DP.

Med Mycol. 2010 Mar;48(2):310-7. doi: 10.1080/13693780903148346.

PMID:
19642052
6.

Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species.

Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP.

J Infect Dis. 2006 Apr 1;193(7):1014-22. Epub 2006 Feb 28. Erratum in: J Infect Dis. 2006 Nov 1;194(9):1342.

7.
8.

Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.

Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP.

J Infect Dis. 2009 May 1;199(9):1399-406. doi: 10.1086/597615.

9.

Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.

Chamilos G, Kontoyiannis DP.

Drug Resist Updat. 2005 Dec;8(6):344-58. Epub 2006 Feb 20. Review.

PMID:
16488654
10.

Animal models of invasive aspergillosis for drug discovery.

Paulussen C, Boulet GA, Cos P, Delputte P, Maes LJ.

Drug Discov Today. 2014 Sep;19(9):1380-6. doi: 10.1016/j.drudis.2014.06.006. Epub 2014 Jun 13. Review.

PMID:
24931219
11.

Efficacy of caspofungin against Aspergillus terreus.

Barchiesi F, Spreghini E, Santinelli A, Fothergill AW, Fallani S, Manso E, Pisa E, Giannini D, Novelli A, Cassetta MI, Mazzei T, Rinaldi MG, Scalise G.

Antimicrob Agents Chemother. 2005 Dec;49(12):5133-5.

12.

Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis.

Chamilos G, Lewis RE, Hu J, Xiao L, Zal T, Gilliet M, Halder G, Kontoyiannis DP.

Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9367-72. doi: 10.1073/pnas.0709578105. Epub 2008 Jun 26.

13.

A nonlethal murine cutaneous model of invasive aspergillosis.

Ben-Ami R, Kontoyiannis DP.

Methods Mol Biol. 2012;845:569-82. doi: 10.1007/978-1-61779-539-8_42.

PMID:
22328405
14.

Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.

Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP.

Diagn Microbiol Infect Dis. 2005 May;52(1):15-20.

PMID:
15878437
15.

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Moen MD, Lyseng-Williamson KA, Scott LJ.

Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010. Review.

PMID:
19275278
16.

Efficacy of Abelcet alone, or in combination therapy, against experimental central nervous system aspergillosis.

Clemons KV, Parmar R, Martinez M, Stevens DA.

J Antimicrob Chemother. 2006 Aug;58(2):466-9. Epub 2006 Jun 7.

17.

AGS3, an alpha(1-3)glucan synthase gene family member of Aspergillus fumigatus, modulates mycelium growth in the lung of experimentally infected mice.

Maubon D, Park S, Tanguy M, Huerre M, Schmitt C, Prévost MC, Perlin DS, Latgé JP, Beauvais A.

Fungal Genet Biol. 2006 May;43(5):366-75. Epub 2006 Mar 13.

PMID:
16531086
18.

Comparative studies on the efficacy of AmBisome and Fungizone in a mouse model of disseminated aspergillosis.

Takemoto K, Yamamoto Y, Ueda Y, Sumita Y, Yoshida K, Niki Y.

J Antimicrob Chemother. 2004 Feb;53(2):311-7. Epub 2004 Jan 16.

19.

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus.

Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, Denning DW.

J Antimicrob Chemother. 2006 Dec;58(6):1198-207. Epub 2006 Oct 27.

20.

Efficacy of anidulafungin against Aspergillus niger in vitro and in vivo.

Calvo E, Pastor FJ, Mayayo E, Guarro J.

Int J Antimicrob Agents. 2011 Oct;38(4):360-3. doi: 10.1016/j.ijantimicag.2011.06.008. Epub 2011 Aug 6.

PMID:
21824751
Items per page

Supplemental Content

Write to the Help Desk